DLL3 and small cell lung carcinoma: Moreover, as DLL3 expression is restricted to the brain but aberrantly expressed in many NE cancers, DLL3 was an early immunotherapeutic target in small cell lung cancer (SCLC)4 and NE prostate cancer5.